terlipressin (vasoconstrictor) — Competitive Intelligence Brief

terlipressin (vasoconstrictor) (terlipressin (vasoconstrictor)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vasopressin analog. Area: Gastroenterology / Hepatology.

marketed Vasopressin analog Vasopressin V1 receptor Gastroenterology / Hepatology Small molecule

Target snapshot

terlipressin (vasoconstrictor) (terlipressin (vasoconstrictor)) — National Science and Technology Council, Taiwan. Terlipressin is a vasopressin analog that selectively activates V1 receptors on vascular smooth muscle to cause vasoconstriction and reduce portal pressure.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
terlipressin (vasoconstrictor) TARGET	terlipressin (vasoconstrictor)	National Science and Technology Council, Taiwan	marketed	Vasopressin analog	Vasopressin V1 receptor
Misoprostol + vasopressin	Misoprostol + vasopressin	University Hospital of the West Indies	marketed	Combination therapy: prostaglandin analog + vasopressor	Prostaglandin receptor (EP3/EP4) and vasopressin V1 receptor
Terlipressin & then Dummy	Terlipressin & then Dummy	Aga Khan University	marketed	Vasopressin analog	Vasopressin V1 receptor
somatostatin or terlipressin	somatostatin or terlipressin	National Science and Technology Council, Taiwan	marketed	Vasoactive peptide	Somatostatin receptors (SSTR) / Vasopressin V1 receptor
norepinephrine+vasopressin	norepinephrine+vasopressin	Peking Union Medical College Hospital	marketed	Vasopressor combination	Alpha-1 adrenergic receptor, beta-1 adrenergic receptor, vasopressin V1 receptor
Terlipressin administration	Terlipressin administration	University Hospital, Rouen	phase 3	Vasopressin analog	Vasopressin V1 receptor
desmopressin MELT formulation	desmopressin MELT formulation	University Hospital, Ghent	marketed	Vasopressin analog / Antidiuretic agent	V2 vasopressin receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vasopressin analog class)

1. Aga Khan University · 1 drug in this class
2. Hamilton Health Sciences Corporation · 1 drug in this class
3. National Science and Technology Council, Taiwan · 1 drug in this class
4. University Hospital, Rouen · 1 drug in this class